Zafgen Inc. apparently learned that waiting only delays the inevitable after its earlier two-day silence following a patient death in its phase III study, bestPWS, evaluating beloranib, a twice-weekly subcutaneously administered drug targeting the methionine aminopeptidase 2a (MetAP2) pathway, in Prader-Willi syndrome (PWS).